Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer

Breast Cancer Research and Treatment

Volumn 123, Issue 3, 2010, Pages 651-660

  Migliaccio, Ilenia ^a,b   Wu, Meng Fen ^a   Gutierrez, Carolina ^a   Malorni, Luca ^a,b   Mohsin, Syed K ^c   Allred, D Craig ^d   Hilsenbeck, Susan G ^a   Osborne, C Kent ^a   Weiss, Heidi ^e   Lee, Adrian V ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c RIVERSIDE METHODIST HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Breast cancer; Estrogen receptor; IRS 1; IRS1; Prognosis

Indexed keywords

CYTOPLASMIC INSULIN RECEPTOR SUBSTRATE 1; ESTROGEN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; NUCLEAR INSULIN RECEPTOR SUBSTRATE 1; PROGESTERONE RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TUMOR VOLUME; BREAST TUMOR; CELL NUCLEUS; CHEMISTRY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TIME; TISSUE MICROARRAY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL NUCLEUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN RECEPTOR SUBSTRATE PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TAMOXIFEN; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952118964     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0632-6     Document Type: Article

References (31)

1. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339(22):1609-1618 (Pubitemid 28536137)
2. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23(30):7721-7735 (Pubitemid 46291836)
3. Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR (2008) Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat 111(1):79-91 (Pubitemid 352009232)
4. Dearth RK, Cui X, Kim HJ, Hadsell DL, Lee AV (2007) Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 6(6):705-713 (Pubitemid 46535683)
5. Jackson JG, White MF, Yee D (1998) Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptorpositive human breast cancer cells. J Biol Chem 273(16):9994-10003 (Pubitemid 28183101)
6. Nolan MK, Jankowska L, Prisco M, Xu S, Guvakova MA, Surmacz E (1997) Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int J Cancer 72(5):828-834 (Pubitemid 27431527)
7. Surmacz E (2000) Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5(1):95-105
8. Surmacz E, Burgaud JL (1995) Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin Cancer Res 1(11):1429-1436
9. Morelli C, Garofalo C, Bartucci M, Surmacz E (2003) Estrogen receptor-Alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene 22(26):4007-4016 (Pubitemid 36819641)
10. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D (1999) Enhancement of insulinlike growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13(5):787-796 (Pubitemid 30645331)
11. Mauro L, Salerno M, Panno ML, Bellizzi D, Sisci D, Miglietta A, Surmacz E, Ando S (2001) Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells. Biochem Biophys Res Commun 288(3):685-689 (Pubitemid 33030084)
12. Molloy CA, May FE, Westley BR (2000) Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 275(17):12565-12571 (Pubitemid 30241403)
13. Cesarone G, Garofalo C, Abrams MT, Igoucheva O, Alexeev V, Yoon K, Surmacz E, Wickstrom E (2006) RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells. J Cell Biochem 98(2):440-450
14. Guvakova MA, Surmacz E (1997) Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 231(1):149-162 (Pubitemid 27187524)
15. Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S, Surmacz E (1999) Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182, 780 in breast cancer cells. Int J Cancer 81(2):299-304 (Pubitemid 29144762)
16. Wu A, Chen J, Baserga R (2008) Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes. Oncogene 27(3):397-403
17. Morelli C, Garofalo C, Sisci D, del Rincon S, Cascio S, Tu X, Vecchione A, Sauter ER, Miller WH Jr., Surmacz E (2004) Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters. Oncogene 23(45):7517-7526 (Pubitemid 39389693)
18. Sisci D, Morelli C, Cascio S, Lanzino M, Garofalo C, Reiss K, Garcia M, Russo A, Ando S, Surmacz E (2007) The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships. Ann Oncol 18(Suppl 6):vi81-vi85
19. Ma Z, Gibson SL, Byrne MA, Zhang J, White MF, Shaw LM (2006) Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol Cell Biol 26(24):9338-9351 (Pubitemid 44904428)
20. Koda M, Sulkowska M, Kanczuga-Koda L, Sulkowski S (2005) Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases. J Clin Pathol 58(6):645-649 (Pubitemid 40814028)
21. Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV, Yee D (1997) Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3(1):103-109 (Pubitemid 27079451)
22. Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D (2000) Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 89(6):506-513
23. Sisci D, Morelli C, Garofalo C, Romeo F, Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Ando S et al (2007) Expression of nuclear insulin receptor substrate 1 in breast cancer. J Clin Pathol 60(6):633-641 (Pubitemid 46975217)
24. Allred DC, Clark GM, Tandon AK, McGuire WL (1993) Immunohistochemistry on histological sections from small (50 mg) samples of pulverized breast cancer. J Histotech 16(2):117-120 (Pubitemid 23164516)
25. Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, le Roanh D, To TV, Qian Z, Love RR, Allred DC (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Mod Pathol 17(12):1545-1554 (Pubitemid 39627082)
26. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474-1481 (Pubitemid 29220854)
27. Lee AV, Zhang P, Ivanova M, Bonnette S, Oesterreich S, Rosen JM, Grimm S, Hovey RC, Vonderhaar BK, Kahn CR et al (2003) Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland. Endocrinology 144(6):2683-2694 (Pubitemid 36629922)
28. Tu X, Batta P, Innocent N, Prisco M, Casaburi I, Belletti B, Baserga R (2002) Nuclear translocation of insulin receptor substrate-1 by oncogenes and Igf-I. Effect on ribosomal RNA synthesis. J Biol Chem 277(46):44357-44365 (Pubitemid 36157871)
29. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155-168 (Pubitemid 28144151)
30. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97(17):1254-1261 (Pubitemid 41535366)
31. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973-1979 (Pubitemid 46606386)